Source: EURLEX
Language: en
Format: md

[**Avis juridique important**](../../../editorial/legal_notice.htm)

*|*

# 31994D0827

**94/827/EC: Commission Decision of 20 December 1994 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 1995, under Council Regulation (EEC) No 594/91, as amended, on substances that deplete the ozone layer** 
  
*Official Journal L 350 , 31/12/1994 P. 0126 - 0137*

  

COMMISSION DECISION of 20 December 1994 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 1995, under Council Regulation (EEC) No 594/91, as amended, on substances that deplete the ozone layer (94/827/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community, especially Article 130s,

Having regard to Council Regulation (EEC) No 594/91 of 4 March 1991 on substances that deplete the ozone layer (1) as amended through Decision (EEC) No 3952/92 (2),

Whereas because of state of the concern for the ozone layer the Commission has decided to phase out certain controlled substances earlier than in the Montreal Protocol commencing on 1 January 1995;

Whereas Regulation (EEC) No 594/91 as amended states the Commission shall determine any essential uses which may be permitted in the Community after 31 December 1994 and any quantities of controlled substances which may be produced, placed on the market or used for their own account by producers for these purposes;

Whereas those essential uses have to be decided for chlorofluorocarbons, as per Articles 10 (1) and 11 (1), fully halogenated chlorofluorocarbons, as per Articles 10 (2) and 11 (2), halons, as per Articles 10 (3) and 11 (3), carbon tetrachloride, as per

Articles 10 (4) and 11 (4) of Regulation (EEC) No 594/91;

Whereas the criteria applied to assessing essential uses are in line with Decision IV/25 of the Fourth Meeting of the Parties to the Montreal Protocol and are:

(a) that a use of a controlled substance should qualify as 'essential' only if:

(i) it is necessary for the health, safety or is critical for the functioning of society (encompassing cultural and intellectual aspects); and

(ii) there are no available technically and economically feasible alternatives or substitutes that are acceptable from the standpoint of environment and health;

(b) that production and consumption, if any, of a controlled substance for essential uses should be permitted only if:

(i) all economically feasible steps have been taken to minimize the essential use and associated emission of the controlled substance; and

(ii) the controlled substance is not available in sufficient quantity and quality from existing stocks of banked or recycled controlled substances, also bearing in mind the developing countries' need for controlled substances;

Whereas the Commission has published Decision 94/563/EC (3) on the quantities of controlled substances allowed for essential uses in the Community determined on the basis of limited applications from Member States which were considered to meet the essential use criteria in line with the above mentioned Montreal Protocol Decision IV/25;

Whereas the Commission has published a notice to users in the European Community of controlled substances allowed for essential uses in the Community in 1995 (4) regarding Council Regulation (EEC) No 594/91, as amended, and has thereby received applications for quantities of controlled substances for essential uses for 1995;

Whereas in the framework of the Montreal Protocol nomination and assessment procedures for essential uses, Parties are requested to identify those users who may take advantage of those essential uses in 1995;

Whereas the Council's common position of the 8 June 1994 on the Commission Proposal COM(93) 202 final (5) foresees in Articles 3, 4 and 7 a procedure whereby the requirements for essential uses can be met accordingly and the Commission shall issue licences to those users identified, according to Article 7, and in accordance with the Committee procedure set out in Article 12 of Regulation (EEC) No 594/91;

Whereas in order to meet those essential laboratory uses identified in Decision 94/563/EC, the Commission shall identify those distributors who may supply the controlled substances for this purpose;

Whereas consequently under this framework a producer may be authorized by the competent authority of the Member State in which its relevant production is situated, to produce the controlled substances for the purpose of meeting the licensed demands presented by the identified users, and that the competent authority of the Member State concerned shall in turn notify the Commission well in advance of any such authorization;

Whereas the identified essential uses fall into four categories, notably: medical uses, solvent uses, laboratory uses and other uses; whereas the quantitatively most important essential use is the medical use of MDIs for the treatment of asthma and other chronic obstructive diseases, as endorsed by the UNEP Technology and Economic Assessment Panel (TEAP) in their March 1994 recommendations to the Parties of the Montreal Protocol;

Whereas Article 12 of Regulation (EEC) No 594/91 sets out the procedure according to which decisions can be taken concerning the implementation of the Regulation;

Whereas the measures provided for in this Decision are in accordance with the opinion of the Committee referred to in Article 12 of the same Regulation;

Whereas the list of essential uses and the quantities of the controlled substances are hereby given in Annex for the information of producer and user industries,

HAS ADOPTED THIS DECISION:

Article 1

Those companies who may take advantage of those essential uses for their own account in 1995 are presented in Annex 2. The allocation of essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, the other fully halogenated chlorofluorocarbons, halons and carbon tetrachloride during the period 1 January to 31 December 1995 shall be as indicated in the Annex 3 (6) hereto.

Article 2

Those companies who may take advantage of the essential uses exemption for laboratory uses, as specified in Decision 94/563/EC.

Article 3

1. This Decision is addressed to the companies listed in Annex 1.

2. This Decision shall apply as follows:

Control period: from 1 January 1995 to 31 December 1995.

Done at Brussels, 20 December 1994.

For the Commission

Yannis PALEOKRASSAS

Member of the Commission

(1) OJ No L 67, 14. 3. 1991, p. 1.

(2) OJ No L 405, 31. 12. 1992, p. 41.

(3) OJ No L 215, 20. 8. 1994, p. 21.

(4) OJ No C 253, 10. 9. 1994, p. 4.

(5) OJ No C 301, 27. 10. 1994, p. 1.

(6) Annex 3 is not published because it contains commercially sensitive information.

PARARTIMA ANEXO 1 / BILAG 1 / ANHANG 1 / 1 / ANNEX 1 / ANNEXE 1 / ALLEGATO 1 / BIJLAGE 1 / ANEXO 1

3M Health Care Ltd

Mr. A.J. Maynard

3M House

Morley Street

Loughborough

GB-Leicestershire LE11 1EP

Akzo Nobel Chemicals BV

De Heer J. Boon

Welplaatweg 12

NL-3197 KS Rotterdam

Laboratorio Aldo-Unión SA

Dr. José Sabater Sanmarti

Angel Guimerà no 123-125

E-08950 Esplugues de Llobregat

(Barcelona)

Sigma Aldrich Company Ltd.

Dr. C. D. Hewitt

Tjheoed Brickyard

New Road

Gillingham

GB-Dorset SP& 4JL

Alcan Deutschland GmbH

Herrn T. Rohling

Werk Goettingen

Hannoversche Strasse 1

D-37075 Goettingen

Laboratorio Astra España

Dr. E. Cabré Matas

Mestre Joan Corrales, 95-105

E-08950 Esplugues de Llobregat

(Barcelona)

Albermale PPC

Monsieur P. Soreau

95, rue Général de Gaulle

BP 116

F-68802 Thann Cedex

Ausimont SpA

Dr. E. Giannetti

Viale Lombardia, 20

I-20021 Bollate (MI)

Bespak PLC

Mr. M.A. Talbot

Bergen Way

Kings Lynn

GB-Norfolk PE30 2JJ

Bie & Bernstsen A/S

Fr. Merete Hermann

Sandkabaekvej 7

DK-2610 Roedovre

Boehringer Ingelheim GmbH

Herrn Dr. Zimmer

D-55216 Ingelheim/Rhein

Caffaro SpA

Dr. M. Cagnoni

Via Friuli, 55

I-20031 Cesano Maderno

Carlo Erba Reactifs

Monsieur J.M. Ervay

BP 616

Chaussée du Vexin

Parc d'affaires des Portes

F-27106 Val-de-Reuil

Carlo Erba Reagenti

Dr. R. Baschieri

Via Winckelmann, 1

I-Milano

DIMSO SA Stryker Implants

Monsieur J. Y. Carentz

Z.I. De Marticot

F-33610 Cestas

CCL Industries Ltd

Dr. T.D. Boardman

Astmoor Industrial Estate

9 Arkwright Road

GB-Runcorn WA7 1NU

Chiesi Farmaceutici SpA

Mastre Pharma Officina Consortile

Dr. P. Chiesi

Via Palermo, 26/A

I-43100 Parma

Société Cordis

Monsieur Fr. René

2905, route des Dolines

F-06921 Antipolis Cedex

Dideco SpA

Ing. Giorgio Sgarbi

Via Statale 12 Nord, 86

I-41037 Mirandola (MO)

Laboratoires Domilens

Madame Jacquemier

321, avenue Jean Jaurès

F-69007 Lyon

Elf Oil UK Ltd

Mr. John Everett

Environmental & Safetey Manager

Milford Haven Refinery

PO Box 10

Milford Haven

GB-Dyfed SA73 3JD

Eurodif Production

Monsieur J. N. Greffe

20, avenue de Ségur

F-75302 Paris 07 SP

Fiat Avio SpA

Dr. F. Davico

Via Nizza, 312

I-10127 Torino

Fisia SpA

Cenbtro Serviizi Ecologici

Dott. I. Scola

Strada Torino, 560

I-10043 Orbassano

Fisons Scientific Equipment

Mr. G. Smith

Product Suppport Manager

Bishop Meadow Raod

Loughborough

GB-Leicestershire LE11 ORG

Fresenius - Smad

Monsieur Ph. Castellino

Directeur « Achats et logistique »

Zone Industrielle de la Ponchonnière

BP 0106

F-69591 L'Arbresle Cedex

Fisons Plc

Pharmaceutical Division

Dr. K. J. Gould

Derby Road 12

GB-Leicestershire LE11 OBB

Fluorochem Ltd

Mr. Peter Whitehead

Wesley Street

Old Glossop

GB-Derbyshire SK13 9RY

Gas-Servei, S.A.

D. L. Ma. Giralt Sans

C/Motores, 151-156 nave no 9

E-08038 Barcelona

G. Pohl-Boskamp GmbH & Co.

Herrn Dr. M. Schmidt

Kieler Strasse 11

D-25551 Hohenlockstedt

Genzyme Phamarceuticals &

Fine Chemicals

Dr. W. A. Stockburn

Manufacturing Operations Manager

Hollands Road

Haverhill

GB-Suffolk CB9 8PU

Glaxo Manufacturing Services Ltd

Mr. Jan Piskaldo

Priory Street

Ware

GB-Hertfordshire SG12 ODJ

Hoechst Danmark A/S

Hr. R.E., Andersen

Islevdalvej 110

DK-2610 Roedovre

Home Office

F1 Division

Mr. Ch. J. Goldie

Room 517

Horseferry House

Dean Ryle Sq.

GB-London SW1P 2AW

JGS Spruehtechnik GmbH

Herrn F. Guck

Im Hemmet 1

D-79664 Wehr Baden

IREOS SpA

Dr. G. Castiello

Via Lagustena 166A

I-Genova

Ismar Chemica Srl

Dr. Fabio de Paz

Via Isocorte, 16

I-16164 Genova

J.T. Baker BV

De Heer F. Leurink

Rijsterborgherweg 20

Postbus 1

NL-7400 AA Deventer

Lancaster Synthesis Ltd.

Dr. M. L. Jasiewicz

A Division of British Tar products

Eastgate, White Land

Morecambe

GB-Lancashire

Landesamt fuer Umweltschutz

Sachsen-Anhalt

Herrn J. Winkler

Dezernatsleiter

Reideburger Str. 47-49

D-06116 Halle

Lacer S.A.

Dr. Eduardo Albors Yodli

C/Sardenya 350

E-080025 Barcelona

Liquid Carbonic

Da Teresa Larrondo Climent

Da Guadalupe Melero Romera

Po. de la Castellana, 147 - 8a Planta

E-28046 Madrid

Luxcontrol SA

Monsieur R. Manzoni

BP 349

L-4004 Esch-sur-Alzette

Medinov

Monsieur Bregand

ZI de Bapaume - BP 55

F-42312 Roanne Cedex

Merck

Herrn Dr. Reiner Hesse

Gen/P

Frankfurter Strasse 250

D-64293 Darmstadt

Merck Ltd.

Mr. P.E. Wall

Merck House

Poole

GB-Dorset BH15 1TD

Miramed S.p.A.

Sig. M. Filipponi

Via Morandi, 16

I-41037 Mirandola (MO)

Mobil Oil Française (F)

Monsieur P. H. Pesqueux

BP 2

F-766330 Notre-Dame-de-Gravenchon

Norton Ltd

Mr. Peter Jordan

IDA Industrial Park

IRL-Waterford

Parke-Davis & Co. Ltd

Mr Neil A. Grumbridge

Usk Road

Pontypool

GB-Gwent NP4 OYH

PCI Membrane Systems Ltd

Mr. A. Eckersley

Laverstoke Mill

Whitchurch

GB-Hants RG28 7NR

Farmacia-Farmitalia Carlo Erba

Dott. G. Salvi

I-63100 Ascoli Piceno

Pharmasol Ltd

Mr. C.W. Brading

North Way

Walworth Industrial Estate

Andover

GB-Hampshire SP10 5AZ

Prolabo

Monsieur H. Doucerain

54, rue Roger Solengro

F-94126 Fontenay-sous-Bois Cedex

Promochem GmbH

Herrn T. Karrer

Mercatorstr. 1

D-46485 Wesel

Resolution Chemicals

Dr Chris Homan

Wedgewood Way

Stevenage

GB-Hertfordshire SG1 4QT

Rhône-Pulenc Chimie

Monsieur J.P. Lanuit

Quai Paul Doumer, 25

F-92408 Courbevoie Cedex

Riedel-de Haën

Herrn. Dr. C. Creutzburg

Postfach 10 02 62

D-30918 Seelze

Ringsted & Semler A/S

Fr. Lykke Andersen

Literbuen 9

DK-2740 Skovlunde

Schering-Plough Labo NV

Mevrouw Ingrid Van de Poel

Industriepark 30

B-2220 Heist-op-den-Berg

Société SDS

Monsieur Ph. Coste

BP 4

Zone industrielle de Valdonne

F-13124 Peypin

Les laboratoires Servier

Monsieur Charles VCIX

326, rue Marcellin Berthelot

BP 227

F-45402 Fleury-les-Aubrais

Sigma-Aldrich Chemie GmbH

Frau Renate Reinhardt

Geschaeftsbereich Fluka

Messerschmittstr. 17

D-89231 Neu-Ulm

Struers Kebo Lab A/S

Fr. Lisbeth Hansen

Roskildevej 16

DK-2620 Albertslund

Studio Chiono S.r.l.

Sig. R. Chiono

Via Ivrea, 42

I-10086 Rivarola C.SE (TO)

Terumo Europe NV

de Heer W. Dierick

Interleuvenlaan 40

B-3001 Leuven

Valeas SpA. Pharmaceuticals

Dr. Virgilio Bernareggi

Via Vallisneri, 10

I-20133 Milano

Société Valois

Monsieur O. Fourment

BP G

F-27110 Le Neubourg

V.A.R.I. SpA

Sig. Roberto Battigello

Via del Pino, 10

I-22057 Olginate (CO)

Vel NV

de Heer R. Kennis

Geldenaaksebaan, 464

B-6001 Leuven

Rathburne Chemicals

Dr. A.C. Mackay

Cabertson Road

GB-Walkerburn EH43 6AU

P. Bacancos S.A. Chemical and

Pharmaceutical Products CO.

Mr. A. Papadakis

21, Omonia Square

GR-10431 Athens

Agmartin H. Margiolis Co.

Mr. Tiniakos

80, Karaiskou Street

GR-Pireaus

M. Roumboulakis SA

Mr Roumboulakis

30, Sokrates, Street

GR-10552 Athens

ANNEX 2

A. MEDICAL USES (i) Production of metered dose inhalers (MDI's) for the treatment of asthma and other chronic obstructive pulmonary diseases (CFC 11, CFC 12, CFC 113, CFC 114).

"(in tonnes)"" ID="1">3M (UK)> ID="2">514"> ID="1">Aldo-Union (E)> ID="2">57,2"> ID="1">Astra (E)> ID="2">17"> ID="1">Bespak (UK)> ID="2">156"> ID="1">Boehringer (D)> ID="2">825"> ID="1">CCL Industries (UK)> ID="2">591"> ID="1">Chiesi Farmaceutics (I)> ID="2">120"> ID="1">Fisons Pharmaceuticals (UK)> ID="2">489"> ID="1">G. Pohl-Boskamp (D)> ID="2">10"> ID="1">Gas Servei (E)> ID="2">140"> ID="1">Glaxo (UK)> ID="2">3 624 "> ID="1">I.G. Spruehtechnik (D)> ID="2">174,5"> ID="1">Lacer (E)> ID="2">0,834"> ID="1">Liquid Carbonic (E)> ID="2">800"> ID="1">Norton (IR)> ID="2">667"> ID="1">Pharmasol (UK)> ID="2">6"> ID="1">Resolution Chemicals (UK)> ID="2">3"> ID="1">Schering-Plough (B)> ID="2">167"> ID="1">Servier (F)> ID="2">124"> ID="1">Valeas (I)> ID="2">187"> ID="1">Valois (F)> ID="2">136"> ID="1">Vari (I)> ID="2">1,7"> ID="1">Total > ID="2">8 810,234">

(ii) Cleaning of medical prosthetics (CFC 113).

"(in tonnes)"" ID="1">Cordis (F)> ID="2">30"> ID="1">Dideco (I)> ID="2">10"> ID="1">Dimso-Stryker (F)> ID="2">0,75"> ID="1">Domilens (F)> ID="2">1,2"> ID="1">Fresenius-Smad (F)> ID="2">80"> ID="1">Medinov (F)> ID="2">1,4"> ID="1">Total > ID="2">123,35">

(iii) Solvent use to prepare silicone solution for dipcoating of medical devices (CFC 113).

"(in tonnes)"" ID="1">Dideco (I)> ID="2">10"> ID="1">Terumo (B)> ID="2">13"> ID="1">Total > ID="2">23">

(iv) Diluent use for ethylene oxide in sterilization of chloramphenicol powder used in eye-ointments (CFC 12).

"(in tonnes)"" ID="1">Parke-Davis & Co. Ltd (UK)> ID="2">0,4224"> ID="1">Total > ID="2">0,4224">

B. SOLVENT USES B.1. CFCs:

(i) Active reagents used to develop fingerprints on paper (CFC 113).

"(in tonnes)"" ID="1">Home Office (UK)> ID="2">9"> ID="1">Total > ID="2">9">

(ii) Inert solvent use for the manufacture of reverse osmosis membrane in the manufacture of food and pharmaceutical products (CFC 113).

"(in tonnes)"" ID="1">PCI (UK)> ID="2">10"> ID="1">Total > ID="2">10">

B.2. Carbon tetrachloride (CCI4):

(i) Production of chlorinated rubber, chlorinated paraffin and as intermediate product for plant treatment preparations.

(ii) Production of chlorinated rubber.

"(in tonnes)"" ID="1">Caffaro (I)> ID="2">20"> ID="1">Total > ID="2">20">

(iii) Production of fibre optics.

(iv) Solvent use for NCI3 in chlorine production.

"(in tonnes)"" ID="1">Albermarle (F)> ID="2">20"> ID="1">Rhône-Poulenc (F)> ID="2">500"> ID="1">Total > ID="2">520">

(v) Purification and absorption distillation of chlorine.

"(in tonnes)"" ID="1">Akzo Nobel (NL)> ID="2">50"> ID="1">Total > ID="2">50">

(vi) Production of terephtaloyldichloride.

"(in tonnes)"" ID="1">Akzo Aramid (NL)> ID="2">72"> ID="1">Total > ID="2">72">

C. LABORATORY USES C.1. CFCs

"(in tonnes)"" ID="1">Acros Chimica NV (B)> ID="2">0,425"> ID="1">Agmarin (GR)> ID="2">0,03 "> ID="1">Ausimont (I)> ID="2">0,2 "> ID="1">Bacacos P. (GR)> ID="2">0,035"> ID="1">Bie & Bern. (DK)> ID="2">1,5 "> ID="1">Carlo Erba (F)> ID="2">2,1 "> ID="1">Carlo Erba (I)> ID="2">6,4 "> ID="1">Fisons Sc. (UK)> ID="2">7,8 "> ID="1">Fluorochem (UK)> ID="2">0,269"> ID="1">Hoechst (DK)> ID="2">0,8 "> ID="1">J. T. Baker (NL)> ID="2">20 "> ID="1">Liquid Carbonic (E)> ID="2">25 "> ID="1">Merck (D)> ID="2">76 "> ID="1">Merck (UK)> ID="2">12 "> ID="1">Prolabo (F)> ID="2">5 "> ID="1">Promochem (D)> ID="2">33 "> ID="1">Rathburn Chemicals (UK)> ID="2">6 "> ID="1">Riedel (D)> ID="2">16 "> ID="1">Roumboulakis M. (GR)> ID="2">0,035"> ID="1">SDS (F)> ID="2">4 "> ID="1">Sigma-Aldrich (F)> ID="2">0,18 "> ID="1">Sigma-Aldrich (D)> ID="2">1,94 "> ID="1">Sigma-Aldrich (UK)> ID="2">2,101"> ID="1">Struers (DK)> ID="2">0,45 "> ID="1">Vel (B)> ID="2">0,02 "> ID="1">Total > ID="2">221,3 ">

(i) Use of CFC 113 in the extraction of organic compounds:

(ii) Quality testing of drying filters in refrigeration systems (CFC 113):

(iii) Research and development of alternative propellants for polyurethane hard foams (CFC 11):

(iv) Use of CFC 113 in the analysis of oil content in water:

C.2. Carbon tetrachloride

"(in tonnes)"" ID="1">Acros Chimica NV (B)> ID="2">0,3 "> ID="1">Agmartin (GR)> ID="2">0,035"> ID="1">Bacacos P. (GR)> ID="2">0,03 "> ID="1">Bie & Bern. (DK)> ID="2">1,9 "> ID="1">Carlo Erba (F)> ID="2">6,5 "> ID="1">Carlo Erba (I)> ID="2">20,5 "> ID="1">Fisons Pharm. (UK)> ID="2">1 "> ID="1">Fisons Sc. (UK)> ID="2">1,5 "> ID="1">J. T. Baker (NL)> ID="2">20 "> ID="1">Merck (D)> ID="2">80 "> ID="1">Merck (UK)> ID="2">23 "> ID="1">Prolabo (F)> ID="2">13,5 "> ID="1">Promochem (D)> ID="2">3 "> ID="1">Rathburn Chemicals (UK)> ID="2">3 "> ID="1">Ringsted (DK)> ID="2">250 liters"> ID="1">Roumboulakis M. (GR)> ID="2">0,035"> ID="1">SDS (F)> ID="2">20 "> ID="1">Sigma-Aldrich (F)> ID="2">0,333"> ID="1">Sigma-Aldrich (D)> ID="2">2,5 "> ID="1">Sigma-Aldrich (UK)> ID="2">1,6 "> ID="1">Struers (DK)> ID="2">0,4 "> ID="1">Vel (B)> ID="2">5 "> ID="1">Total > ID="2">205,033 + 250 liters">

(i) Use in water analysis:

(ii) Use in the testing of gas filters:

(iii) Use in halogenation reaction in research laboratories:

(iv) Use as standards for control of chemical products and monitoring of organic pollution of water, air, etc.:

(v) Use as an extraction agent and solvent for analysis for unforseable purposes:

(vi) Laboratory and research uses general: research on ODSs thermodynamics, thermophysics, chemistry kinetics and toxicology:

D. MISCELLANEOUS USES

"(in tonnes)"" ID="1">Eurodif Prod. (F)> ID="2">30"> ID="1">Total > ID="2">30">

PARARTIMA ANEXO 4 / BILAG 4 / ANHANG 4 / 4 / ANNEX 4 / ANNEXE 4 / ALLEGATO 4 / BIJLAGE 4 / ANEXO 4

Aldrich Chemical Company

Dr. C. D. Hewitt

The Old Brickyard

New Road

Gillingham

UK-Dorset SP8 4JL

Ausimont SpA

Dr. E. Giannetti

Viale Lombardia 20

I-20021 Bollate (MI)

Bie & Berntsen A-S

Mr. Merete Hermann

Sandbaekvej 7

DK-2610 Roedovre

Carlo Erba Reactifs

Mr. J.M. Ervay

BP 616

Chaussée du Vexin

Parc d'affaires des Portes

F-27106 Val-de-Reuil

Carlo Erba Reagenti

Dr. R. Baschieri

Via Winckelmann 1

I-Milano

Chiesi Farmaceutici SpA

Master Pharma Officina Consortile

Dr. P. Chiesi

Via Palermo 26/A

I-43100 Parma

Fiat Avio SpA

Dr. F. Davico

Via Nizza 312

I-10127 Torino

Fisia SpA

Centro Servizi Ecologici

Dott. I. Scola

Strada Torino 50

I-10043 Orbassano

Fisons Pharmaceuticals plc

Dr. K.J. Gould

12 Derby Road

Loughborough

Leicestershire LE11 0BB

Fisons Scientific Equipment

Mr. G. Smith

Product Support Manager

Bishop Meadow Road

Loughborough

Leicestershire UK - LE11 ORG

Fluorochem Ltd

Mr. Peter Whitehead

Wesley Street

Old Glossop

Derbyshire SK13 9RY

Hoechst Danmark A/S

Mr. R. E. Andersen

Islevdalvej 110

DK-2610 Roedovre

IREOS SpA

Dr. G. Castiello

Via Lagustena 166A

I-Genova

Ismar Chemica SRL

Dr. Fabio de Paz

Via Isocorte 16

I-16164 Genova

J.T. Baker BV

De Heer F. Leurink

Rijsterborgherweg 20

Postbus 1

NL-7400 AA Deventer

Lancaster Synthesis Ltd

Dr. M. L. Jasiewicz

A Division of British Tar products

Eastgate, White Lund

Morecambe

UK-Lancashire

Merck

Dr. Reiner Hesse,

Gen/P

Frankfurter Strasse 250

D-64293 Darmstadt

Merck Ltd

Mr. P. E. Wall

Merck House, Poole

UK-Dorset BH15 1TD

Miramed SpA

Mr. M. Filipponi

Via Morandi 16

I-41037 Mirandola (MO)

Prolabo

Mr. H. Doucerain

54, rue Roger Solengro

F-94126 Fontenay-sous-Bois Cedex

Promochem GmbH

Mr. T. Karrer

Mercatorstr. 51

D-46485 Wesel

Riedel-de Haën

Dr. C. Creutzburg

Postfach 10 02 62

D-30918 Seelze

Ringsted & Semler A/S

Lykke Andersen

Literbuen 9

DK-2740 Skovlunde

Société SDS

Mr. Ph. Coste

BP 4

Zone industrielle de Valdonne

F-13124 Peypin

Sigma-Aldrich Chemie GmbH

Ms Renate Reinhardt

Geschaeftsbereich Fluka

Messerschmittstr. 17

D-89231 Neu-Ulm

Sigma-Aldrich (F)

Mr. Denis Micol

F-38070 Saint-Quentin-Fallavier

Struers Kebo Lab A/S

Ms Lisbeth Hansen

Roskildevej 16

DK-2620 Albertslund

Studio Chiono SRL

Mr. R. Chiono

Via Ivrea 42

I-10086 Rivarola C. SE (TO)

VEL NV

Mr. R. Kennis

Geldenaaksebaan 464

B-3001 Leuven

Rathburne Chemicals

Dr. A.C. Mackay

Caberston Road

Walkerburn

Scotland EH 43 6AU

J. T. Baker BV

De Heer F. Leurink

Rijsterborgherweg 20

Postbus 1

NL-7400 AA Deventer

Sigma-Aldrich Chemie GmbH

Ms Renate Reinhardt

Geschaeftsbereich Fluka

Messerschmittstr. 17

D-89231 Neu-Ulm

Liquid Carbonic

Mme Teresa Larrondo Climent/

Mme Guadeloupe Melero Romera

Pso. de la Castellana, 147 - 8 a Planta

E-28046 Madrid

[Top](#document1)